Saniona AB (publ) (STO:SANION)

Market Cap	1.36B
Revenue (ttm)	338.43M
Net Income (ttm)	216.89M
Shares Out	136.09M
EPS (ttm)	1.91
PE Ratio	5.21
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	887,900
Average Volume	932,988
Open	10.04
Previous Close	9.96
Day's Range	10.02 - 10.94
52-Week Range	2.51 - 11.60
Beta	0.86
RSI	56.03
Earnings Date	Aug 28, 2025

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SANION